Withdrawal phenomenon with the antiandrogen casodex - Editorial comment Journal Article
| Authors: | Scher, H. I.; Kelly, W. K. |
| Article Title: | Withdrawal phenomenon with the antiandrogen casodex - Editorial comment |
| Abstract: | Total androgen blockade with castration and antiandrogens has become the primary therapy in metastatic prostate carcinoma. Several reports have been published on the flutamide withdrawal syndrome with a favorable response in patients with progression of disease after lengthy remission while taking combined hormone therapy. The experience with withdrawal of the experimental nonsteroidal antiandrogen casodex * in 3 patients is reported. All patients received casodex monotherapy initially, then luteinizing hormone-releasing hormone analogues were added on progression of disease (bone scan and prostate specific antigen (PSA)) and eventually casodex was withdrawn on further progression of disease (PSA and bone scan). © 1995 American Urological Association, Inc. |
| Keywords: | aged; aged, 80 and over; clinical feature; case report; drug withdrawal; antineoplastic agents; prostate specific antigen; withdrawal syndrome; gonadorelin; cancer hormone therapy; prostate-specific antigen; prostatic neoplasms; bicalutamide; flutamide; anilides; bone scintiscanning; prostate carcinoma; human; male; priority journal; article; substance withdrawal syndrome |
| Journal Title: | Journal of Urology |
| Volume: | 153 |
| Issue: | 3 Suppl. |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 1995-03-01 |
| Start Page: | 1072 |
| End Page: | 1073 |
| Language: | English |
| PROVIDER: | scopus |
| DOI: | 10.1016/S0022-5347(01)69870-7 |
| DOI/URL: | |
| Notes: | Article -- See DOI 10.1016/s0022-5347(01)67644-4 and PMID 7531785 for article under discussion and text of the comment -- Export Date: 28 August 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work